Innovative Technologies for the Treatment of Pulmonary and Heart Failure
A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT05090930
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 100 participants
- Sponsor
- National Research Center for Cardiac Surgery, Kazakhstan
- Registry
-
NCT05090930
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Kazakhstan
- Registry status
- Unknown status
Technical summary
Registry record NCT05090930. Non-randomized; no masking; primary purpose treatment. Start 2021-01-01 (actual); primary completion 2023-07-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Innovative Technologies for the Treatment of Pulmonary and Heart Failure
- Condition
- Cardiogenic Shock
- Condition
- Ventricular Arrythmia
- Condition
- Cardiac Arrest With Successful Resuscitation
- Condition
- Sepsis
- Condition
- Multiple Organ Failure
- Condition
- Pulmonary Failure
- Condition
- Decompensated Heart Failure
- Condition
- Acute Heart Failure
- Intervention (Device)
- HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection
- Intervention (Device)
- CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber
- Lead sponsor
- National Research Center for Cardiac Surgery, Kazakhstan
- Collaborator
- Ministry of Education and Science, Republic of Kazakhstan
Record details
- Record id
cardio:ct-nct05090930- Content hash
22e7dffcdb3be5c7827f9129c6c87fc7e554d17efd9b9b65aa58e56c88f6d8e3